NCT07600320Enrolling by invitation
Fareon Open Label Device Clinical Trial
Microtesla Magnetic Therapy (MMT) Treatment of Cognitive Impairment: Open Label Pilot Study
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 May 2026
- Start date
- 11 May 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Diseases
- Alzheimer disease, Long COVID and ME/CFS
- NCT number
- NCT07600320
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 11 May 2026 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Change in anti-depressant or other psychoactive medication or dose in the last 90 days
- Any medical, psychiatric, or neurological condition, or concurrent treatment, that in the opinion of the Principal Investigator would interfere with study participation, interpretation of results, or pose additional risk to the participant.
Other illness
- History of seizure disorder
Other
- Individual who meets any of the following criteria will be excluded from participation in this study:
- Enrollment in another interventional clinical trial in the last 90 days or during the study period
- Cranially implanted devices or metal
- Pacemaker
- Pregnant or plan to become pregnant during the study as indicated by proof of a positive pregnancy test
- Inability to achieve appropriate positioning of the study device on the head
Criteria the registry did not label
- IncInclusion Criteria:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Any sex/gender
- 16 years of age or older
- English Speaking
- Experiencing symptoms of at least self-reported mild cognitive impairment associated with a confirmed diagnosis of a condition such as Long COVID, Traumatic Brain Injury, other Acquired Brain Injuries, and other neurodegenerative diagnoses including but not limited to Alzheimer's disease
- Individuals of childbearing age agreeing to use a highly effective form of birth control for the duration of their participation
- Willing and able to sign informed consent or have a parent or LAR able to sign informed consent form
- Willing and able to attend all study visits virtually or in person
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.